Cyfuse Biomedical K.K.

As of June 30, 2026, Cyfuse Biomedical K.K. carries a market capitalization of 5.55B, placing it among publicly traded companies globally. Its enterprise value stands at 3.39B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Cyfuse Biomedical K.K.'s next confirmed earnings release is scheduled for November 13, 2026.

As of June 30, 2026, Cyfuse Biomedical K.K. has 10.09M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Cyfuse Biomedical K.K. maintains a current ratio of 3.87, meaning it holds 3.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Cyfuse Biomedical K.K.'s stock has declined approximately 7.19% over the past 52 weeks. The 50-day moving average sits at 606.16, while the 200-day moving average is 605.62.

As of June 30, 2026, Cyfuse Biomedical K.K. holds 3.39B in cash and equivalents against 1.23B in total debt, resulting in a net debt position of -2.16B. Total book value stands at 2.62B, with working capital of 2.65B providing operational flexibility.